Questions List

Do you want more visits to your site? I succeeded and it works with this https://zeep.ly/RgLhLPosted onJuly 18, 2021 12:41 am

Posted onJune 21, 2021 1:50 pm

Hello YOU NEED HELP TO BUILD SEO BACKLINKS FOR: cme-congresses.com ? WE SELL HIGH-QUALITY DOFOLLOW POWERFUL BACKLINKS WITH HIGH DOMAIN AUTHORITY, PA, TF, CF... ► Rank Higher In Google (google backlinks, DoFollow backlinks, SEO DoFollow backlinks) ► Rank Higher Video in Youtube & Google (youtube backlinks, video backlinks, video embedded) ► Rank Higher GMB In Google Maps (Google maps backlinks, GMB maps backlinks, GMB embedded, NAP embedded) ► Rank Higher Images In Google (google images backlinks, google backlinks) You Can Increase Traffic to your websites which will lead to a higher number of customers and much more sales for you. If You Are Interested, I'm waiting for your response here => seosubmitter@mail.com Thanks, Scotty StephensonPosted onJune 19, 2021 1:46 pm

testPosted onMay 18, 2021 9:01 am

Posted onMay 17, 2021 8:11 am

Posted onMay 17, 2021 8:11 am

Posted onMay 17, 2021 8:11 am

Posted onMay 17, 2021 8:11 am

Hello cme-congresses.com Make Delicious African Soups Like a Pro in your own kitchen! Indulge in becoming an expert at creating various and flavorful forms of Ghanaian Soups using tasty ingredients such as Tomatoes, Peanuts, Spinach, and more, through easy-to-follow cookbooks! Browse Our Books https://zeep.ly/bLjg1 Thanks, Berenice Roney If you no longer wish to hear from us, please reply to this email.Posted onMay 16, 2021 9:56 pm

Posted onMay 15, 2021 10:40 pm

Posted onMay 15, 2021 10:40 pm

Posted onMay 15, 2021 10:40 pm

Posted onMay 15, 2021 10:40 pm

Posted onMay 15, 2021 10:40 pm

Send my cme certificate in email. Thank you. There is no myeloma specialist in my reageon. How i can send some one for short training programmes. Posted onMay 9, 2021 4:44 pm

Posted onMay 9, 2021 4:41 pm

Good night . Have a good time Posted onMay 9, 2021 4:40 pm

CONGRATULATIONS!!!Posted onMay 9, 2021 4:39 pm

Posted onMay 9, 2021 4:36 pm

CONGRATS to Nurse Sarah & Cindy of the patients Advocacy Group (Kamuyu, Kenya) Posted onMay 9, 2021 4:31 pm

Changes in viral tropism/ VIRUS tropism for malignant cell/myeloma cell(abnormal plasma cells) Can you talk about this question ? M.L.A.Balea/Bucharest.Posted onMay 9, 2021 4:06 pm

Congratulations on excellent talk on MM therapy. I hope the toxic effects certain drugs will be reduced in the future new drugs.Posted onMay 9, 2021 4:05 pm

Is there any research on the primary lymph node events in myeloma?Posted onMay 9, 2021 4:01 pm

There's a Treg cell barrier for immunotherapy in myeloma patients Can we : 1: autologous T cell collection 2:then lymphodepletion with Cyc +- fludarabin 3: and then BITE therapy with or after autologous T cell infusion.Posted onMay 9, 2021 3:59 pm

Awesome lecture Ken - so in 2030 - how will frontline therapy change and which of these drugs will be combined to enhance the CURE fraction - and does autoSCT go away?Posted onMay 9, 2021 3:59 pm

Leif Bergsagel and Marta Chesi just published in Blood Cancer Discovery that IMiDs in combination with BCMA bispecific antibodies in an immunocompetent model led to T cell exhaustion. IN contrast low dose cyclophosphamide and BSAB's were synergistic. Would you care to comment on this?Posted onMay 9, 2021 3:55 pm

JAK inhibition has been shown to impair NK cell function. Would this not be counterproductive if using this to induce CD38 expression?Posted onMay 9, 2021 3:50 pm

Though not a question but an agreement with Dr. Anderson about Bortezomib on apoptosis & I feel this should be the path to focus on when addressing cancers. (Kamuyu, Kenya)Posted onMay 9, 2021 3:44 pm

Great session F+SPosted onMay 9, 2021 3:30 pm

may be Mekfku (AN)Posted onMay 9, 2021 3:29 pm

No need of pos medication is an advantage for Isa?Posted onMay 9, 2021 3:26 pm

Do you see any advantage to use Isa in the population that presents the renal function compromised?Posted onMay 9, 2021 3:25 pm

Congratulations to the organizing company for allowing this open discussion tackling some practical issues. Comy is the only Congress where we see this. Very good Posted onMay 9, 2021 3:23 pm

This debate and dialogue is very nice and useful. Bravo and good choice of speakersPosted onMay 9, 2021 3:21 pm

For a 83year old MM lenalidomide refractory and fit patient no cardiopathy, do you prefer DaraKDex ? Or Dara PomDex?Posted onMay 9, 2021 3:16 pm

Any logic or data on combining Anti CD38 Ab +Elo or in future with BispecificPosted onMay 9, 2021 3:16 pm

Can we rechanllenge a patient with anti CD38 after an Ab treatment free interval?Posted onMay 9, 2021 3:13 pm

Would you consider giving another CD38 if they have been exposed (but are not refractory) to a prior CD38? If so, how do you define exposure vs refractory?Posted onMay 9, 2021 3:13 pm

Len refractory-does length and dose of Len exposed mater Posted onMay 9, 2021 3:12 pm

Pt question - If in slow biochemical relapse on Rev 5mg would you consider this Len exposed or refractory? Posted onMay 9, 2021 3:12 pm

Do you think is possible to use Isa imediatelly after Dara?Posted onMay 9, 2021 3:11 pm

In Len refractory patient with extramedullary disease-what would you recommend Posted onMay 9, 2021 3:10 pm

Posted onMay 9, 2021 3:09 pm

We still have many patients who received Len only for 2 or 3 years. What is the best relapse combination for these patients?Posted onMay 9, 2021 3:05 pm

Optimism has been randomized against vel Dex which is not a good control. Therefore the results are not valid. Do you agree? The only valid results are those of ICARIA and APOLLOPosted onMay 9, 2021 3:02 pm

If i use DaraVTD for induction before transplant , can I use Isatuximab Pom Dex at first relapse?Posted onMay 9, 2021 2:57 pm

What will happen if we show that antiCD38 +VRD are better than Dara Rd?Posted onMay 9, 2021 2:54 pm

Are there any data about the combination of isatuximab with velcade like in castor trial?Posted onMay 9, 2021 2:51 pm

Posted onMay 9, 2021 2:48 pm

Ikema results look better than candor. What is the explanation?Posted onMay 9, 2021 2:48 pm

Can you combine anti CD38 and venetoclax?Posted onMay 9, 2021 2:48 pm

In a patient who is sensitive to melphalan, would you give at first relapse a salvage with a few cycles using an antibody and then a second auto?Posted onMay 9, 2021 2:44 pm

Is COPD a contra indication to Isatuximab? How to premedicate?Posted onMay 9, 2021 2:42 pm

Isatuximab has a different mechanism of action compared to Dara. But how can we see this difference in the clinic?Posted onMay 9, 2021 2:41 pm

IKEMA results are really very good in terms of PFS and safety. Should we offer IsaKD to all first relapse patients instead of IsapomDex?Posted onMay 9, 2021 2:39 pm

Very nice arguments for the Len resistant patientsPosted onMay 9, 2021 2:38 pm

I pt can't use Carf due to cardiotoxicity....do we have a new PI? Will IXaz work in these combos?Posted onMay 9, 2021 2:23 pm

Patient question: All these small molecules perform better combined with Bortezomib. Can you keep reusing Bortez in these different combos or with subsequent lines of tx will pt become refractory i?Posted onMay 9, 2021 2:19 pm

Great presentations - I think we all are excited about immunotherapy and that TCE's will dominate all treatment spaces (ND, early relapse, RR), but which of these drugs will combine favorably with the immunotherapies - which of these are least immunosuppressive or have mechanistic optimism for combination or may enhance cure? Posted onMay 9, 2021 2:19 pm

Dr Mohty can you safely advise selinexor combined combinations instead of pomalidomide in 17p patients in relapse settings? (Anil Ozturkmen, Turkey)Posted onMay 9, 2021 2:17 pm

if t(11;14) on FISH is not demonstrated at relapse when it was evident at diagnosis, do we attribute as sampling error and still go ahead with venetoclax if originally intended ? Posted onMay 9, 2021 2:15 pm

What are the optimal partners to be combined with venetoclax?Posted onMay 9, 2021 2:07 pm

How do you explain the high infections rate in the Bellini trial?Posted onMay 9, 2021 2:05 pm

Posted onMay 9, 2021 2:04 pm

Should we offer venetoclax to all t(11,14) patients as soon as the frontline setting?Posted onMay 9, 2021 2:04 pm

To Dr Mohty: can you summarize the symptomatic mesures that help improve the tolerance of selinexorPosted onMay 9, 2021 1:53 pm

Why do you call Iberdomide CelMod and not IMID?Posted onMay 9, 2021 1:45 pm

Why not randomizing Melflufen to melphalan?Posted onMay 9, 2021 1:42 pm

Why not using melflufen in the auto transplant setting?Posted onMay 9, 2021 1:37 pm

We have Melflufen, selinexor and belantamab in the end stage disease. How to choose among these options?Posted onMay 9, 2021 1:37 pm

Melflufen is reserved for advanced stage disease, but this is when patients have a low bone marrow reserve. Thus, this is not logical and the drug should be positioned earlier. Any thoughts?Posted onMay 9, 2021 1:35 pm

Posted onMay 9, 2021 1:25 pm

Not a question : happy to see more and more women in this forum. Anne DD patient from FRANCEPosted onMay 9, 2021 1:19 pm

What are the challenges you encountered during the work and how are can these challenges be controlled in future studies. I am Dabie Kwabena from Ghana Posted onMay 9, 2021 1:17 pm

Is the strong dual epitope targeting of BCMA by Cilta Cel responsible for the chronic neurotoxicity? Is there really BCMA expression in the basal ganglia?Posted onMay 9, 2021 1:15 pm

Hi Noopur, Excellent talk as usual. Given the plethora of options in RRMM where do you think CART fits in ? Part of the 1st line as consolidation after ASCT or as replacement to extend that PFS right after the induction to allow for an excellent long QOL for patients or do you think we exhaust the triple class agents and then use them so that the survival for proportion of patients ? Mouli, SingaporePosted onMay 9, 2021 1:09 pm

How to improve the CAR T cell results in the advanced setting?Posted onMay 9, 2021 12:53 pm

What is the recommended bridging therapy prior to CAR T cells? Any thoughts on conventional chemo like bendamustine?Posted onMay 9, 2021 12:50 pm

Why cilia cell data look better than Ide cell?Posted onMay 9, 2021 12:48 pm

Can anti-CD38 antibodies harm CAR T cell expansion given their long half life?Posted onMay 9, 2021 12:43 pm

Any ongoing trials or data with dual CAR T cells?Posted onMay 9, 2021 12:42 pm

Is there a risk of CRS if LEN is initiated early after CAR T cells?Posted onMay 9, 2021 12:41 pm

Is it relevant to measure MRD as early as 1 month after CAR T cells?Posted onMay 9, 2021 12:40 pm

Is there any rationale to administer bispecifics for maintenance after CAR T cells?Posted onMay 9, 2021 12:38 pm

If you have a choice between 3 drugs targeting BCMA: CAR T, belantamab and bispecific. What would be your first choice?Posted onMay 9, 2021 12:37 pm

As a patient many thanks to you too ! Anne FRance Posted onMay 9, 2021 12:31 pm

Is there evidence that TIGIT is unregulated on T cells following treatment with BiTEs? If so, could anti-TIGIT therapy help?Posted onMay 9, 2021 12:23 pm

Does it make sense to use sequential T cell engagers if a potential mechanism of resistance is exhaustion? You may change the engager but you still have the same T cells. Posted onMay 9, 2021 12:06 pm

Have the non-BCMA antibodies mentioned shown any peripheral neuropathy?Posted onMay 9, 2021 12:04 pm

Will non-BCMA novel therapies be relegated to patients who have previously failed BCMA therapies?Posted onMay 9, 2021 12:02 pm

We see SNC toxicity with Bites, but PN with the Bispecific: any explanation?Posted onMay 9, 2021 11:57 am

Please comment on the mechanism of action of a trispecific antibody?Posted onMay 9, 2021 11:52 am

Is there a rationale for targeting one antigen versus another one first?Posted onMay 9, 2021 11:48 am

Now that a second BCMA bi-specific antibody has shown periph. neuropathy, do we think that is a class effect? Is it due to the target or MoA?Posted onMay 9, 2021 11:47 am

Any role for ATRA in BCMA regulation of expression?Posted onMay 9, 2021 11:41 am

Can you comment on the exact role of soluble BCMA?Posted onMay 9, 2021 11:41 am

PVD was compared to VD in a less heavily pretreated population. Is this a fair comparisonPosted onMay 9, 2021 11:34 am

Sorry, Venetoclax question was from Luciano Costa, USA Posted onMay 9, 2021 11:32 am

Tom, brilliant presentation. If patient's MM harbor t(11;14), would you (and where) include Venetoclax? With dex or with other partners?Posted onMay 9, 2021 11:32 am

What is the definition of a time frame for antibody-free treatment ?Posted onMay 9, 2021 11:30 am

Hi Tom Excellent Talk as usual ! With so many regimes available, where do you see CART therapy fit in this treatment paradigm? As Consolidation post induction therapy or as a stand alone relapsed treatment regime or do you foresee it being used in combination with other agents esp IMiDs ? Posted onMay 9, 2021 11:28 am

The results of IKEMA look better than Candor: is this a correct statement?Posted onMay 9, 2021 11:28 am

Do yo prefer adding Carfilzomib to reach mrd negativity in high risk patients who is having Dara-pom-dex? (Anil Ozturkmen, Turkey)Posted onMay 9, 2021 11:27 am

What do you think the place of elotuzumab in RRMM setting ? From Sung-Soo Yoon, Korea.Posted onMay 9, 2021 11:27 am

If a patient failed a daraKd regimen at first relapse, is IsaPomdex a relevant subsequent option?Posted onMay 9, 2021 11:26 am

In a triplet combination how to ensure to which drug the patient is resistant to?Posted onMay 9, 2021 11:25 am

Phenomenal summary, thank you so much Posted onMay 9, 2021 11:25 am

When do you think blood MRD will replace marrow MRD? Meral BeksacPosted onMay 9, 2021 10:19 am

If patients are on VTd or VRd should we be taking a treatment break to be able ot vaccinate?Posted onMay 9, 2021 10:15 am

We vaccinate before Auto transplant, should we be RE -vaccinating after auto transplant with 2 doses again? Should we look for response to vaccinae? Mamta Garg UK Posted onMay 9, 2021 10:14 am

For Dr Pavia; Do you consider to adapt your maintenance for high risk patients if patient cannot reach mrd negativity after sct for a long time (like 1-2 years after sct)? Your maintenance is IRd. Do you consider to chance it to VRd, KRD or add Dara quadruplets? (Dogan Taskiran, Turkey) Secondary Mgus is a benign phenomennon. Do you consider this phenomennon also an obstacle for mrd evaluation? Posted onMay 9, 2021 10:12 am

how to vaccinate a patient on treatment ?, thank youPosted onMay 9, 2021 10:12 am

Make the voice louder can not hear properly please. Posted onMay 9, 2021 10:01 am

Does persistence of FDG avidity on PET post therapy or ASCT despite marrow MRD negativity inform any treatment decision ? Posted onMay 9, 2021 9:52 am

Posted onMay 9, 2021 9:50 am

WB-LDCT is the part of PET-CT imaging but some our PET-CT reports doesn't cover most of skull and reports does't contain WB-LDCT results. Should we warn Nuclear medicine experts about this?Posted onMay 9, 2021 9:48 am

Do you use MRI to evaluate myeloma response?Posted onMay 9, 2021 9:41 am

Should we combine pet scan and MRD evaluation?Posted onMay 9, 2021 9:40 am

For MRD measerument with NGF, do you also look for normal healthy plasma cell count or proportion to monovlobal plasma cells? Does this effect to Progression?Posted onMay 9, 2021 9:39 am

For MRD session: Can you elaborate more about sensitivity and specificity of testing MRD by NGF or NGS in peripheral blood and bone marrow? Patient may not be keen on bone marrow samples!Posted onMay 9, 2021 9:37 am

How to handle the anxiety related to the MGUS diagnosis in a 45 y old woman?Posted onMay 9, 2021 9:32 am

How to handle light chain MGUS?Posted onMay 9, 2021 9:28 am

How do you monitor MGUS in an 87 y old patient?Posted onMay 9, 2021 9:28 am

Can mass spectrometry replace the invasive MRD in the BM?Posted onMay 9, 2021 9:27 am

Can mass spectrometry replace the invasive MRD in the BM?Posted onMay 9, 2021 9:27 am

management of a young patient who developed heart failure secondary to twice weekly bortezomib administration, thank youPosted onMay 9, 2021 9:24 am

Can NGF allow MRD detection to the 10-6 level?Posted onMay 9, 2021 9:20 am

Can NGF allow MRD detection to the 10-6 level?Posted onMay 9, 2021 9:20 am

Was Carfilzomib ever tried as sub cut injection?Posted onMay 9, 2021 9:19 am

Was Carfilzomib ever tried as sub cut injection?Posted onMay 9, 2021 9:19 am

Is heavy smoking and severe COPD a contra indication to Daratumumab?Posted onMay 9, 2021 9:15 am

How to prevent thrombosis after a first episode of TE under lenalidomide?Posted onMay 9, 2021 9:12 am

How to define resistance to anti-CD38 antibodies from a clinical standpoint?Posted onMay 9, 2021 9:07 am

Do you see less infusion related reactions with one anti CD38 drug versus another?Posted onMay 9, 2021 8:58 am

Is split dosing of daratumumab for the first infusion a valid option ?Posted onMay 9, 2021 8:57 am

Do you recommend any specific cardiac monitoring for a patient without any comorbidities but receiving Carfilzomib?Posted onMay 9, 2021 8:56 am

Can you please comment on the avoidance of DEX during the covid pandemic. Did you see a decreased incidence of response?Posted onMay 9, 2021 8:52 am

Is a third injection of the covid vaccine recommended in myeloma?Posted onMay 9, 2021 8:51 am

Selinexor has been available in the US for some time now- where is it finding its place in the treatment of R/R MM based on STORM and BOSTON data?Posted onMay 9, 2021 8:46 am

Posted onMay 8, 2021 10:43 pm

Very nice sessions today my congratulations to all all the speakers and discussion groups. Good night Dr zahid hussain Posted onMay 8, 2021 7:04 pm

Posted onMay 8, 2021 7:00 pm

Posted onMay 8, 2021 7:00 pm

Your opinion yes/no -to search MRD in cell preserved for ASCT? M.Balea/Bucharest Posted onMay 8, 2021 7:00 pm

Why we never speak about the positive impact of MRD negativity on patient psychology? This is very important for the patient!Posted onMay 8, 2021 6:51 pm

Is the non-randomized approach used in the MASTER trial completely valid? Or do we still need to see randomized data before de-escalating treatment?Posted onMay 8, 2021 6:45 pm

For Dr. Fonseca: Lets say High Risk complete response patient with VR maintenance cannot reach MRD- after 18-24 cycles of maintenance after sct. Do you consider to add Daratumumab or change Velcade to Carfilzomib instead of waiting relapse? Posted onMay 8, 2021 6:44 pm

Is MRD valid at time of relapse?Posted onMay 8, 2021 6:43 pm

Lets say High Risk CR patient with VR maintenance cannot reach MRD- after 18-24 cycles of maintenance after sct. Do you consider to add Daratumumab or change Velcade to Carfilzomib instead of waiting relapse? I know no rct for that (Anil Ozturkmen, Turkey)Posted onMay 8, 2021 6:37 pm

Given the cost of myeloma therapy, why people are complaining about MRD cost?Posted onMay 8, 2021 6:29 pm

We use MRD in lymphoma, in AML, in ALL, in CLL. Why such a hot controversy in myeloma about MRD? Apologies I am a young doctorPosted onMay 8, 2021 6:26 pm

I have a patient who is MRD positive after one year of Len maintenance. Should I change the maintenance therapy?Posted onMay 8, 2021 6:23 pm

Should we combine MRD measurement with PET scan?Posted onMay 8, 2021 6:20 pm

Do you have pharmaco economic studies in relation to the cost effectiveness of the use of MRD?Posted onMay 8, 2021 6:17 pm

Is still the message that it does not mater how you achieve MRD negativity once you are negative true (AN) Posted onMay 8, 2021 6:16 pm

As for relapse and importance of MRD testing is the type and especially the number of relapse i.e 1 vs 3 important as for MRD significance (AN)Posted onMay 8, 2021 6:14 pm

Do you modify a maintenance therapy based on MRD positivity?Posted onMay 8, 2021 6:12 pm

Is MRD useful in a 85 years old patient?Posted onMay 8, 2021 6:10 pm

How do you define MRD sustainability?Posted onMay 8, 2021 6:09 pm

What is the recommended frequency for MRD assessment after auto transplant?Posted onMay 8, 2021 6:08 pm

What are the advantages of NGS MRD versus NGF?Posted onMay 8, 2021 6:07 pm

What is the optimal threshold for MRD evaluation?Posted onMay 8, 2021 6:04 pm

Posted onMay 8, 2021 5:58 pm

For patient who received KRd ASCT and R maint what will you give with DARA at second line Posted onMay 8, 2021 5:58 pm

Is there a value for Thalidomide therapy in Len refractory patients?Posted onMay 8, 2021 5:57 pm

Th]s ‘s me MUTLU. ARAT. TRPosted onMay 8, 2021 5:53 pm

Th]s ‘s me MUTLU. ARAT. TRPosted onMay 8, 2021 5:53 pm

FDG PET sensitive enough? Role of dara-zirkonyum PET scan (Ola Lundgren)Posted onMay 8, 2021 5:51 pm

I Think that we must search MRD in the stem cells preserved for the autotransplant. M.Balea/ BucharestPosted onMay 8, 2021 5:48 pm

I Think that we must search MRD in the stem cells preserved for the autotransplant. M.Balea/ BucharestPosted onMay 8, 2021 5:48 pm

What are you doing when MRD negative become MRD positive? Posted onMay 8, 2021 5:41 pm

Many of patients on DRd relapse out of the BM with BM MRD neg-and no secreting MM. Do you think we have to repeat PET regulary in some patient (high risk?) to catch these EM relapses? Posted onMay 8, 2021 5:40 pm

Many of patients on DRd relapse out of the BM with BM MRD neg-and no secreting MM. Do you think we have to repeat PET regulary in some patient (high risk?) to catch these EM relapses? Posted onMay 8, 2021 5:39 pm

Jean Luc harousseau France I am not connected but I wanted to ask the question of the interest of MRD assessment out of a clinical trial to adat therapy since for instance we don't know what is the optimal strategy when MRD is <0 during maintenancdPosted onMay 8, 2021 5:35 pm

In clinical practice, at what time points are you testing for MRD in frontline transplant eligible patients? And do you use flow or NGS?Posted onMay 8, 2021 5:34 pm

At relapse setting do you decide to stop or not stop DEXA according to MRD result?Posted onMay 8, 2021 5:33 pm

Lets say High Risk CR patient with VR maintenance cannot reach MRD- after 18-24 cycles of maintenance. Do you consider to add Daratumumab (Dara-VRd) or change Velcade to Carfilzomib (KRd) instead of waiting relapse? I know no rct for that (Anil Ozturkmen, Turkey)Posted onMay 8, 2021 5:27 pm

What is the ideal protocol that you would apply to a young and fit patient to achieve the longest survival?Posted onMay 8, 2021 5:21 pm

The recommendations are usually always politically correct, eg. Pomalidomide based approaches. But how to choose in practice assuming all options are available?Posted onMay 8, 2021 5:17 pm

What is the relevance of a randomized trial which has used a very weak and non relevant control arm to show superiority?Posted onMay 8, 2021 5:12 pm

Should we perform pet scan in addition to MRD all time?Posted onMay 8, 2021 5:07 pm

What is your opinion about early measurement of MRD after CAR T cells?Posted onMay 8, 2021 5:06 pm

Are we ready to use MRD to escalate or de-escalate myeloma therapy?Posted onMay 8, 2021 5:05 pm

Can we use MRD as a cost-saving tool?Posted onMay 8, 2021 5:04 pm

Question to Dr. Miguel: Re: NGS MRD testing does the molecular thumb print evolve , ie is the baseline test to recognize the IGH clones still valid as the disease progress ? Posted onMay 8, 2021 5:03 pm

Why regulatory bodies are not accepting MRD as an endpoint for trials?Posted onMay 8, 2021 5:03 pm

Posted onMay 8, 2021 5:00 pm

To treat MM we must (need) have criteria.(IMWG) To treat or not treat SMM ? This is a paradox. The question is to search a non toxic/ treatment. It is possible?Posted onMay 8, 2021 4:47 pm

To treat MM we must (need) have criteria.(IMWG) To treat or not treat SMM ? This is a paradox. The question is to search a non toxic/ treatment. It is possible?Posted onMay 8, 2021 4:47 pm

Which end organ damage? Anemia? Posted onMay 8, 2021 4:36 pm

A 75 old waman with SMM since 2013. In 2018-20% MM FISH 1q amp K/K ratio-20 IGAK less than 1 gr/dl IN 2020 IgA.K less than 1 gr/dl butK/L ratio-50, and BM-50%, Still wait or active anti-MM therapy?Posted onMay 8, 2021 4:35 pm

Posted onMay 8, 2021 4:35 pm

What is the rationale for waiting for bi-specifics or car-t to treat HR SMM? Posted onMay 8, 2021 4:35 pm

Posted onMay 8, 2021 4:32 pm

Posted onMay 8, 2021 4:32 pm

A patient treated on lenalidomide for SMM, when progresses to myeloma, can you re-introduce lenalidomide based regimen or would they be refractory?Posted onMay 8, 2021 4:32 pm

What should be the dose of Lenalidomide for High risk SMM? Dr. Humayra Nazneen , BangladeshPosted onMay 8, 2021 4:31 pm

if you have a patient with HR SMM, and you treat for 2 years with Rd, and do not achieve CR, what would you do? Kwee Yong, UKPosted onMay 8, 2021 4:30 pm

What is your opinion of the definition of SMM... should it disapear as disease and to move from MGUS or indolent PC disease to MM? Shoulld the definition of Myeloma-defining events be expanded incorporrating mollecular markers?Posted onMay 8, 2021 4:28 pm

how the early treatment affects the health economy? Posted onMay 8, 2021 4:27 pm

What is the target figure of an Organ-damage free survival if treating a SMM?Posted onMay 8, 2021 4:25 pm

What is the target figure of an Organ-damage free survival if treating a SMM?Posted onMay 8, 2021 4:25 pm

the Mayo score is valid only at Dx of SMM? What about dinamyc risk stratification?Posted onMay 8, 2021 4:24 pm

the Mayo score is valid only at Dx of SMM? What about dinamyc risk stratification?Posted onMay 8, 2021 4:24 pm

how about dexa alone or thalidomide alone in the treatment of High risk SMM for ecominic issue ?Posted onMay 8, 2021 4:23 pm

Humberto Martínez-Cordero from National Cancer Institute of Colombia. The approach to treat oncologic diseases is framed in prevention, early detection, diagnosis, treatment and rehabilitation and palliative care. Talking about Multiple Myeloma, smoldering correspond to a early detection and talking about Smoldering multiple myeloma as a apart disease the approach must be different. Early detection of myeloma (smoldering) must be treated to cure, and trials have demonstrated this? Smoldering as a apart disease: treatments have demonstrated improve overall survival? I guess must be no treated. Posted onMay 8, 2021 4:19 pm

Hi Dr. Rajkumar, How do you respond to Dr. Leleu's comment that the initial steep curve (2-year risk of progression almost 80%) has been mostly taken care of by the SLiM-CRAB criteria by including myeloma-defining biomarkers? Posted onMay 8, 2021 4:19 pm

I have a patient in a clinical trail who receive DARA for HR SMM for 2.5 years and now the M protein is increaing- When to start anti MM therapy? Would it be VRd?Posted onMay 8, 2021 4:16 pm

I have a patient in a clinical trail who receive DARA for HR SMM for 2.5 years and now the M protein is increaing- When to start anti MM therapy? Would it be VRd?Posted onMay 8, 2021 4:16 pm

If patient has (low or high risk) smoldering myeloma and monoclonal antibody related symptoms (neuropathy, immuneparesis related reccurent infections) would you treat? (Vedat Aslan,Turkey)Posted onMay 8, 2021 4:14 pm

To Dr Xavier. When it will be prime time for treatment of smoldering?Posted onMay 8, 2021 4:14 pm

How long you follow a HR SMM before you decide to start Rd/R? Posted onMay 8, 2021 4:13 pm

Posted onMay 8, 2021 4:12 pm

When you observed SMM and after 6 years the R/L ratio is slowly increasing to above 100- continue to follow? Posted onMay 8, 2021 4:12 pm

Debbie (US). If treated a patient with high risk smoldering MM, how long do you treat? Until progression like MM or for a fix duration?Posted onMay 8, 2021 4:07 pm

Are there any genomic features that can help refine the risk of smoldering myeloma?Posted onMay 8, 2021 4:07 pm

If we treat smoldering myeloma with lenalidomide only than what will be the definition of relapse? will chemical relaps will be enough to say that this patient is lenalidomide resistant, relaps myeloma? Posted onMay 8, 2021 4:07 pm

What is the evidence behind the 2/20/20 scoring?Posted onMay 8, 2021 4:06 pm

Did you integrate quality of life measures in the smoldering trials?Posted onMay 8, 2021 4:04 pm

Can you address the issue of fixed duration of therapy versus continuous in smoldering myeloma?Posted onMay 8, 2021 4:03 pm

treating early with lenalidomide how will impact later treatment treatments?Posted onMay 8, 2021 4:02 pm

May be the question is not whether we should treat or not , but what is the optimal treatment… Rev Dex is not optimalPosted onMay 8, 2021 4:02 pm

Is smoldering myeloma benign disease or malign myeloma under control of immune system? Can Treg/CD8 T cell proportion immune-profile show us the character of smoldering myeloma? Posted onMay 8, 2021 4:00 pm

Posted onMay 8, 2021 3:57 pm

This trio is amazing. They can continue discussing for a full day. Good choice COMY. This is only Congress where we see this kind of sessions thanks to the visionary organizers Posted onMay 8, 2021 3:45 pm

We need more of this kind of sessions to show the reality on the ground. Posted onMay 8, 2021 3:37 pm

Very nice discussion, bravoPosted onMay 8, 2021 3:30 pm

If something worked during covid, why it should not work outside covid?Posted onMay 8, 2021 3:27 pm

Did you capture quality of life data in the real world registry?Posted onMay 8, 2021 3:23 pm

What is the percentage of black patients included in this RWE registry?Posted onMay 8, 2021 3:20 pm

Can you comment on the combination of ixa and Dara as published by the Dutch group?Posted onMay 8, 2021 3:18 pm

Can you provide details on the safety of KRD in your Tchécoslovaquia registry? (This is where we fear toxicity, not with IRD)Posted onMay 8, 2021 3:15 pm

In the Dara Vel Dex combination, do you recommend the switch from velcade to Ixazomib ?Posted onMay 8, 2021 3:08 pm

Posted onMay 8, 2021 3:05 pm

Can you share the long term follow up results of the tourmaline and Pollux trials in the relapsed setting?Posted onMay 8, 2021 3:01 pm

How to balance convenience with efficacy?Posted onMay 8, 2021 2:58 pm

I love the unique format of this session. Please do more sessions like this.Posted onMay 8, 2021 2:57 pm

Do you treat biochemical relapse in the elderly to avoid organ damage?Posted onMay 8, 2021 2:55 pm

Ixasazomib and revlimid is the treatment of choice in this elderly patient Posted onMay 8, 2021 2:54 pm

Why don’t you propose CAR T cells for this patient?Posted onMay 8, 2021 2:51 pm

The ideal approach would be in this case KRD induction and then switch to IxaRd, but this is not how the trials were donePosted onMay 8, 2021 2:49 pm

During the COVID19 pandemic, IxaRd proved to be convenient and effective. Can the panel comment on this?Posted onMay 8, 2021 2:47 pm

This first case is about a very aggressive and bad prognosis patient (relapse in less than 12 months after auto as published by the UK group). Thus, you have to use your best available option. And try quadruplet actually…Posted onMay 8, 2021 2:45 pm

Posted onMay 8, 2021 2:42 pm

Congratulations for such a timely topic. We have to move away from the domination of RCT and take into account the diversity of patients.Posted onMay 8, 2021 2:39 pm

Posted onMay 8, 2021 2:37 pm

Posted onMay 8, 2021 2:37 pm

Do you consider that RWE data should become manadatory before or after drug approval?Posted onMay 8, 2021 2:36 pm

Regarding randomized control trial, there has been "queries" surrounding them due to in some instances where participants aren't served with all information & sometimes not all data captured during the trials are shared with regulators. (Kamuyu, Kenya)Posted onMay 8, 2021 2:33 pm

In the real world, the Rd data were better than the original registration trials. Can you please comment on thisPosted onMay 8, 2021 2:31 pm

Can you comment please on PROs? Posted onMay 8, 2021 2:26 pm

As a patient, I think that randomized trials are missing the diversity of the patients with myeloma. We have to fight for changing this system Posted onMay 8, 2021 2:23 pm

How can we convince authorities to integrate RWE in the approval process?Posted onMay 8, 2021 2:21 pm

This mysterious Thalydomid(Distaval)/Lenalidomid. M.B./BucharestPosted onMay 8, 2021 2:15 pm

Posted onMay 8, 2021 2:10 pm

Are there any data about second primary malignancies with the Drd regimen. A. Garcia (Spain)Posted onMay 8, 2021 2:09 pm

Posted onMay 8, 2021 1:47 pm

longer term treatment with PI is needed for Non transplant eligible (longer induction and manteinance ) would you see the possibility of trials addressing non Inferiority efficacy end points and convenience besides safety endpoint of oral triplets vs VRD for this population? Posted onMay 8, 2021 1:43 pm

Posted onMay 8, 2021 1:35 pm

IN THE ELDERLY SINCE PFS FOR IRD AND VRD ARE SAME, DO YOU THINK WE CAN CHOOS IRD AS 1 ST LİNE ESPECİALLY IN THE COVİD ERA OR IN GENEREAL AS WELLPosted onMay 8, 2021 1:35 pm

Can you please comment on the assessment of cardiovascular risk prior to the use of Carfilzomib in the transplant ineligible population? Thank you.Posted onMay 8, 2021 1:31 pm

Do you see any role for rd alone in the elderly?Posted onMay 8, 2021 1:25 pm

Is there any efficacy of LEN 5 mg in mantenance (redution because of toxicity(Posted onMay 8, 2021 1:23 pm

How to explain the failure of the Ixa rd trial while the absolute PFS was meaningful?Posted onMay 8, 2021 1:22 pm

How to choose between Dara VMP and Dara RdPosted onMay 8, 2021 1:21 pm

Is VRD light validated in a prospective fashion?Posted onMay 8, 2021 1:20 pm

IS IT REASOABLE TO ADMİNİSTER THE 1 ST COURSES OF BORTEZOMİBE INTRAVENOUSLY İN İNDUCTION INSTEAD OF SCPosted onMay 8, 2021 1:19 pm

For newly dx Tpt-ineligible pts with t(4;14), between DRd and VRd , what is your preference ? Posted onMay 8, 2021 1:17 pm

HR patient in real life- DRd? VRd? D-VRd? Posted onMay 8, 2021 1:13 pm

IN PATİENTS OVER 75 RECEİVİNG VRD, İS THE DOSE OF LENA 15 MG?Posted onMay 8, 2021 1:07 pm

Lina (Morocco) : what is the number of VCD cycles in the elderly, thank youPosted onMay 8, 2021 1:02 pm

Which myeloma type responds to high dose Melphalan better? Plasma cells with low versus high PCLI ? Meral BeksacPosted onMay 8, 2021 12:58 pm

What was the rate of adherence to double transplant in the emn trial? -Chris Strouse USAPosted onMay 8, 2021 12:58 pm

Posted onMay 8, 2021 12:57 pm

Do Mel200 and Mel140 have too much difference in tandem setting especially patient have CR before sct? (Anil Ozturkmen, Turkey)Posted onMay 8, 2021 12:57 pm

In fit high-risk patients, which PI+IMiD combination do you favor for post-transplant maintenance: KR, VR, or IR? (Country-USA)Posted onMay 8, 2021 12:50 pm

Do you really give Dara-VTd in 21 cycles ( as in the CASTIOPHEA) although all the neurotoxicity?Posted onMay 8, 2021 12:50 pm

IN HIGH RİSK MYELOMA , İS IXAZOMİBE AS RELAİABE AS BORTEZOMİB?Posted onMay 8, 2021 12:42 pm

DO YOU GİVE LENALİDOMİDE CONTINUOSLY OR FOR 21 DAYS? SHOULD WE CHOOSE TO GIVE 15 MG Posted onMay 8, 2021 12:39 pm

Posted onMay 8, 2021 12:35 pm

Lina el mekkoudi (morocco) : number of VCD cycles in elderly subjects not eligible for autologous transplantation, thank youPosted onMay 8, 2021 12:33 pm

What are the data about Ixa Len maintenance ?Posted onMay 8, 2021 12:32 pm

Posted onMay 8, 2021 12:32 pm

With all the new treatments (CART...) Do you still think we have to recommend tandem for HR patients?Posted onMay 8, 2021 12:32 pm

When MRD is negative after ASCT, would you skip consolidation? Posted onMay 8, 2021 12:31 pm

IN TRANSPLANT ELLİGİBLE PATİENTS WİTH CLOSE TO VGPR AFTER 4 VRD DO YOU STİLL SUGGEST I COMPLETE İT TO 6 CYCLES BEFORE PROCEEDİNG TO AUTO HSCT?Posted onMay 8, 2021 12:27 pm

Why the Perseus schedule was different from the griffin one?Posted onMay 8, 2021 12:22 pm

Why in Griffin the Dara dose was every week for 4 cycles?Posted onMay 8, 2021 12:19 pm

Should we be concerned about a successful stem cell harvest after Lenalidomide containing induction regimens? How often is Plerixafor required to support post - Lenalidomide harvests? Dr NE Blesing -- UKPosted onMay 8, 2021 12:18 pm

Is really VRD better than VTD?Posted onMay 8, 2021 12:18 pm

Should we offer double auto to t(4,14) patients?Posted onMay 8, 2021 12:16 pm

Can you comment on Dara VCD?Posted onMay 8, 2021 12:10 pm

Lina el mekkoudi (Morocco): management of a 36-year-old patient who developed heart failure secondary to twice-weekly bortezomib administration , thank you Lina El Mekkoudi (Morocco): what is the optimal treatment in a patient on hemodialysis and with heart failure, is the presence of thrombosis a contraindication to thalidomide thank you Posted onMay 8, 2021 12:03 pm

Is it better to give 4 cycles of quadruplet or 6 cycles of VRD?Posted onMay 8, 2021 12:01 pm

If basic ICE score evaluation is not 10 score- how do you decide the grade of ICANS?Posted onMay 8, 2021 11:48 am

Zsombor Bende, MD (Hungary) Dear Prof. Mateos, what is the percentage of NYHA IV cardiac failure during CAR T cell therapy ? Posted onMay 8, 2021 11:46 am

Please comment on the value of treatment free interval after car T cells.Posted onMay 8, 2021 11:37 am

What kind of bridge to use while waiting for car T cells?Posted onMay 8, 2021 11:34 am

How to interpret MRD results early after CAR T cells?Posted onMay 8, 2021 11:33 am

Should we use maintenance after car T cells?Posted onMay 8, 2021 11:31 am

All myeloma patients do not have same bone lesions. Some patients have more lytic lesions and some patients don’t have. Do lytic lesions have important role for immune escape of myeloma cells? Bone lesions give myeloma cells more niches to escape from myeloma cells. (Vedat aslan Turkey)Posted onMay 8, 2021 11:23 am

Wiil you consider not take to a clinical trail of Antibody-drug conjugated if you think next treatment will be CART? Posted onMay 8, 2021 11:21 am

For a NDMM transplant elegible, who progress during VRD induction (after 3 cycles) Which combination would you Consider More appropiate for this bortezomib and lenalidomide refractory patient?Posted onMay 8, 2021 11:20 am

A paient who recieved VRd followed by ASCT and R maint and relapse and the patient is young and Fit - Will you choose DVd or DKd?Posted onMay 8, 2021 11:18 am

After clonal evolution in MM is there data with any mode of therapy that we can go back to less malignant clone and can this dictate our choice (AN)Posted onMay 8, 2021 11:16 am

What would you choose as second line for a patient who receieved KRג-ASCT-KR- R maint and progress on R MAINT. DARA with ?Posted onMay 8, 2021 11:15 am

What would you choose as second line for a patient who receieved KRג-ASCT-KR- R maint and progress on R MAINT. DARA with ?Posted onMay 8, 2021 11:15 am

In Len refractory patients, how to choose between the different pomalidomide based combinations?Posted onMay 8, 2021 11:12 am

1 In choosing the treatment for relapsing pts does it mater if they yes or no underwent Auto (AN) 2 In Len refractory does it mater the length and total exposure to Lena (AN) 3 In late relapses with all new compounds is there still a sense to go back to the treatment (drugs) patient initially response too AN) Posted onMay 8, 2021 11:12 am

Posted onMay 8, 2021 11:07 am

Len is often proposed in maintenance. Once the patient is refractory (or AE) what to you propose ? Anne Delmond patient from France Posted onMay 8, 2021 11:06 am

Very engaging sympo. CongratulationsPosted onMay 8, 2021 11:06 am

In case of only 2 years of revlimid maintenance, is the patient resistant?Posted onMay 8, 2021 11:03 am

Immune therapie works when we have low disease burden. Why reserving car T cells for end stage disease?Posted onMay 8, 2021 11:03 am

Can you comment on the combination of CAR T cells and Imids?Posted onMay 8, 2021 10:57 am

We have a therapy based on mechanisms for repairing damage to DNA?(gene repair mechanism) M.Balea/Bucharest/Romania.Posted onMay 8, 2021 10:55 am

Accordng our own data there are a lot new genetic abberation in MM patient during therapy including posttransplat period. How do tou think whether it does matter for treatment shoosung?Posted onMay 8, 2021 10:52 am

Wish all symposia from companies were like this brilliant one! We need more of these thoughtful discussionsPosted onMay 8, 2021 10:52 am

Can you please expand on celmodsPosted onMay 8, 2021 10:50 am

Hello, my name is Maxwell Duah(PhD), joining form China. Thank you for the nice ongoing presentation , please, is there anyway to make the presentation(PPT) clear, its very blurry from my side. Even after shifting from using the mobile phone to using PC.Posted onMay 8, 2021 10:43 am

We have a therapy based on mechanism for repairing damage to DNA? M.Balea/Romania.Posted onMay 8, 2021 10:31 am

Though not a question but acknowledging all presenters as I ingest "harmoniously" all what has been presented in-respect to angiogenesis as far as avascular-vascular switching of tumors. (Kamuyu, Kenya).Posted onMay 8, 2021 10:20 am

In relapse setting for high risk patients; do you prefer Dara/k/pom/dex or isa/k/pom/dex regimens initially or add pom lately? In last Ash we saw dara/k/pom/dex is very effective achieving high mrd negativity in relapse (Anil Ozturkmen, Turkey)Posted onMay 8, 2021 10:20 am

Question to Aurore Congratulations for an excellent long term data in IFM2009 Study. Though entirely different studies, in the context of CASSIOPEIA study how do you interpret or compare IFM2009 study ? Which induction / consolidation / maintenance schedules would you prefer in SRMM/ HRMM ?Posted onMay 8, 2021 10:20 am

In real life- after an induction with KRd-ASCT or Dara-VRd and ASCT, what is your maint approach? R alone or KR after KRd or DR vs R alone after D-VRd? Posted onMay 8, 2021 10:16 am

Would any of these triplet or quadruplet therapies work after you progress on these agents and further to a relapse following Car-T? Or once you start immunotherapies it’s too late for DaraKR or Isa? Adrian, USAPosted onMay 8, 2021 10:14 am

Posted onMay 8, 2021 10:11 am

KRD compared to VRD did not bring any benefit. Why Dara-KRD is then preferred to Dara VRD in the trials?Posted onMay 8, 2021 10:09 am

To Dr Perrot: the EMN auto trial showed an OS benefit, but not the IFM one. Why?Posted onMay 8, 2021 10:05 am

How to choose between CANDOR and IKEMA?Posted onMay 8, 2021 10:04 am

Posted onMay 8, 2021 9:52 am

Should Dara-VRD become the standard of care for induction prior to transplant?Posted onMay 8, 2021 9:34 am

Prof Kaufman, did you have many patients who did not proceed with ASCT and what were their outcomes ? Thank youPosted onMay 8, 2021 9:33 am

What about the use of Carfilzomib in EMD? Dr. Bruno Garibaldi, University of Catania, ItalyPosted onMay 8, 2021 9:07 am

@Artur: What is your ideall melfluffen-basedd combo in EMD patients? Posted onMay 8, 2021 9:07 am

Posted onMay 8, 2021 9:06 am

Posted onMay 8, 2021 9:00 am

Melflufen is highly effective in EMD. Can you comment?Posted onMay 8, 2021 8:57 am

Are there specific patients who can benefit from belantamab?Posted onMay 8, 2021 8:51 am

How do you treat patients on hemodialysis? What is your opinion on bisphosphonate and denosumab use in this patient group? Ayse Salihoglu (Turkey)Posted onMay 8, 2021 8:44 am

@Touzeau: Would you recommend the use of venetoclax in t(11;14) in spite of the fact it is not approved by neither FDA nor EMEA? the posiitive data in Bellini are coming from a very small subgroup of patients.Posted onMay 8, 2021 8:34 am

How to explain the high infectious mortality rate with venetoclax?Posted onMay 8, 2021 8:28 am

Who are the patients to whom you would still propose panobinostat?Posted onMay 8, 2021 8:24 am

Should we reserve venetoclax to the t(11,14) subgroup?Posted onMay 8, 2021 8:24 am

@Katja Weisel: Would you use Elotuzumab after anttiCD38 mABs? Posted onMay 8, 2021 8:23 am

What is the Elotuzumab in myeloma given the modest current efficacy results compared to other options?Posted onMay 8, 2021 8:22 am

Posted onMay 8, 2021 5:13 am

Is polycythemia villi a type of MM? What stage between MGUS-SMM -MM does it occur? Prof Mohty. Henry KARUGU Kenya, East Africa. Posted onMay 8, 2021 3:43 am

Posted onMay 8, 2021 2:22 am

Boa tarde Posted onMay 7, 2021 7:53 pm

Posted onMay 7, 2021 6:54 pm

How we can download certificate of daily sessions Posted onMay 7, 2021 6:49 pm

Posted onMay 7, 2021 6:45 pm

Can we stop PI in Mrd negative (long term) high risk patients? (Anil Ozturkmen, Turkey) Posted onMay 7, 2021 6:38 pm

The "siren song of MRD" is certainly applicable in CAR-T treatment. (Jack Aiello, USA)Posted onMay 7, 2021 6:36 pm

can MALDI-TOF (peripheral test) replace bone marrow MRD NFG?Posted onMay 7, 2021 6:36 pm

Could you comment on the curative potential of allogeneic transplants?Posted onMay 7, 2021 6:35 pm

Can we wake the immune senescence with Interferon? Meral Beksac Posted onMay 7, 2021 6:34 pm

Since myeloma is a disease of the elderly, how much of a role does age-related decline in immune status has in elusiveness of "cure"? K. Suryanarayan (US)Posted onMay 7, 2021 6:17 pm

VRD results above age 75 are relatively poor compared to those achieved in the MAIA trial. Why recommend VRD?Posted onMay 7, 2021 6:09 pm

Can the panel comment on the MANHATTAN and MASTER trials which allowed to achieve a high rate of MRD negativity…Posted onMay 7, 2021 6:00 pm

How do you define an “acceptable “ safety profile in SMM? Where do you set the bar?Posted onMay 7, 2021 5:50 pm

Despite the randomized trials, very few people (if any) are treating high risk SMM. Why is this? Can all experts be wrong?Posted onMay 7, 2021 5:48 pm

Posted onMay 7, 2021 5:40 pm

What the ideal treatment package in a transplant eligible patient to achieve long term PFS?Posted onMay 7, 2021 5:40 pm

Posted onMay 7, 2021 5:27 pm

cPosted onMay 7, 2021 5:22 pm

aPosted onMay 7, 2021 5:22 pm

cPosted onMay 7, 2021 5:20 pm

cPosted onMay 7, 2021 5:20 pm

dPosted onMay 7, 2021 5:20 pm

So where do you position allogeneic SCT in WM? Who benefits from an alloSCT ? Refractory ?MYD88 WT perhaps? Posted onMay 7, 2021 5:09 pm

Fixed time treatment vs continuous therapy ? depends on the patient subgroup?Posted onMay 7, 2021 5:06 pm

Posted onMay 7, 2021 5:05 pm

FEHMİ Posted onMay 7, 2021 5:04 pm

Posted onMay 7, 2021 5:04 pm

IF YOU DONT DO TRANSPLANT 1ST LİNE, DO YOU COLECT SETM CELL AT TIME OF CR ACHIEVEMENT OR DO YOU POSTPONE AND COLLECT AT RELAPSE? Posted onMay 7, 2021 5:04 pm

Posted onMay 7, 2021 5:03 pm

There are reports of major adverse events while treating IgM associated amyloidosis patients with LPL. Dr. Treon himself has published a negative trial. Whats the panelists opinion on the use of BTKi in IgM associated amyloidosis ? Also any mechanistic explanation for the adverse outcomes ? Mouli, SingaporePosted onMay 7, 2021 5:03 pm

What is the mechanism of action of doxicyclune in treating the disease.Posted onMay 7, 2021 5:01 pm

you have seen cutaneous vasculitis as a manifestation of WM (Paola from Argentina(Posted onMay 7, 2021 5:00 pm

very nice presentation whole day . Discussion was very informative and detailed one . Thank you all . Dr zahid hussain Posted onMay 7, 2021 4:59 pm

MW and kidney insuffitiency and MM symptoms how to treat?Posted onMay 7, 2021 4:56 pm

Is there any remaining role for auto transplant in amyloidosis or Waldenstrom?Posted onMay 7, 2021 4:50 pm

Is there any added value for acalubrutinib compared to inbrutinib?Posted onMay 7, 2021 4:45 pm

Should we offer Daratumumab +VCD to all amyloidosis patients?Posted onMay 7, 2021 4:43 pm

Any role for other BTK inhibitors in Waldenstrom;?Posted onMay 7, 2021 4:42 pm

Is the IgM level a good indicator of the Waldenstrom disease activity?Posted onMay 7, 2021 4:41 pm

What is the criteria to start therapy in Waldenstrom ?Posted onMay 7, 2021 4:41 pm

Do you recommend heart transplantation in AL AMYLOIDOISIS stage IV Mayo clinic? If yes when and where?Posted onMay 7, 2021 4:30 pm

In the light of effective therapy with good opportunity for organ response, do you think there is a role of left ventricular assist device as a bridge for amyloidosis pts with severe heart failure while awaiting organ response ? Posted onMay 7, 2021 4:27 pm

For how long do you indicate doxycycline ? (Paola from Argentina)Posted onMay 7, 2021 4:25 pm

**************Posted onMay 7, 2021 4:10 pm

Aren’t alkylators, even next gen like melflufen, higher risk for secondary malignancies than immunotherapies? Adrian, USAPosted onMay 7, 2021 3:55 pm

How does the neuropathy reported with Pfizer's bispecific recently compare to the neurotoxicity with bispecifics/CAR-Ts? Posted onMay 7, 2021 3:53 pm

What is the data for use of bortezomib, every 2 weeks for up to 2 years for maintenance? Bortezomib has become generic outside EU, it is cheaper then Len, some hospitals and countries are using this in comb with dexa. What is the opinion of this panel pleasePosted onMay 7, 2021 3:52 pm

Posted onMay 7, 2021 3:51 pm

Posted onMay 7, 2021 3:50 pm

How durable (long lasting) are responses to FcRH5 BiTEs compared to GPRC5D and BCMA targets? Adrian, USAPosted onMay 7, 2021 3:50 pm

Currently when you use Dara-VRd, ASCT and achived CR MRD neg. How would you continue maint therapy- DR or R? Posted onMay 7, 2021 3:49 pm

Posted onMay 7, 2021 3:48 pm

We heard in the last session how persistent treatment potentially fuels development of resistance. What do the panelists think of time limited treatment with immunotherapy agents rather than continuing treatment for ever...patients hate it ! Mouli, SingaporePosted onMay 7, 2021 3:47 pm

We heard in the last session how persistent treatment potentially fuels development of resistance. What do the panelists think of time limited treatment with immunotherapy agents rather than continuing treatment for ever...patients hate it ! Mouli, SingaporePosted onMay 7, 2021 3:47 pm

So do you feel comfort to give DARA without Dex preperation in the long run? Posted onMay 7, 2021 3:46 pm

If we assume all myeloma patients are candidate of T cell therapy, Should we collect peripheral T cells at the beginning of Myeloma treatments? Is there difference with T cells of treatment naive patient and T cell of heavily treated patient?Posted onMay 7, 2021 3:27 pm

If it is possible to use new agents in second line of RRMM patients which kind would you prefer? What kinds of predictors or parameters whoud you use?Posted onMay 7, 2021 3:22 pm

Is it appropriate to switch treatment on induction phase before ASCT if just PR achieved (not VGPR or better)?Posted onMay 7, 2021 3:20 pm

Are there any association between CAR-T therapy effectiveness and NGS data?Posted onMay 7, 2021 3:17 pm

The results of the CARTITUDE CAR look better than the KARMMA CAR: is this a true statement?Posted onMay 7, 2021 3:15 pm

How to differentiate between the different CAR T cell constructs?Posted onMay 7, 2021 3:13 pm

Antigenic stimulation of B cells results in the production of plasma cells & MM is caused by proliferation of a single clone of plasma cells which secrete large amounts of one type of Ig with a constant structural composition & physical properties. From such expression, would environmental factors determine in its (MM) engagement (treatment & cure) it being there seem to be "triggers". Question to Drs. Mateos & Mikhael (Kamuyu, Kenya) Posted onMay 7, 2021 3:10 pm

Should we collect T cells ASAP to anticipate a CAR T therapy later on?Posted onMay 7, 2021 3:07 pm

Bispecifics and CAR T cells require the presence of T cells, while ADcs act like chemotherapy. Is this an indicator of the sequence of these drugs?Posted onMay 7, 2021 3:05 pm

What is the optimal design to compare CAR T cells to auto transplant?Posted onMay 7, 2021 3:00 pm

When using Len in maintenance, is it about immune control? Or direct anti tumor activity?Posted onMay 7, 2021 2:53 pm

While we want to stimulate the immune system, we keep on using DEX which is the most potent immunosuppressive agent. How to reconcile this ?Posted onMay 7, 2021 2:52 pm

Has anyone looked at age-related changes in the immune system in myeloma patients and what role that may play if any? K. Suryanarayan (US)Posted onMay 7, 2021 2:27 pm

If a patient has a good immune response to CMV by ELISPOT, is this a good surrogate marker for the immune system status in myeloma?Posted onMay 7, 2021 2:12 pm

if you have 500 T cells ,could you do a car T therapy? Stratos GreecePosted onMay 7, 2021 2:09 pm

Are there secreted microenvironment biomarkers that can predict the progression of SMM to MM and the effect of preventive treatments? Posted onMay 7, 2021 2:05 pm

Posted onMay 7, 2021 2:03 pm

Did someone among the panel see an MGUS which disappeared spontaneously ?Posted onMay 7, 2021 2:00 pm

How to get rid of Dex to improve the immune status of patients?Posted onMay 7, 2021 1:58 pm

how could be fixed the exhausted T cells? stratos GreecePosted onMay 7, 2021 1:54 pm

Should we collect T cells early in the course of the disease in anticipation of a CAR T therapy?Posted onMay 7, 2021 1:52 pm

What kind of trial one can run in high risk MGUS?Posted onMay 7, 2021 1:48 pm

Is T cell exhaustion is only in myeloma microenvironment or also can we see in peripheral T cells? Can we collect peripheral T cells before treatment of immunotherapy and give back after immunotherapy? By these way we can use lymphodepletion after T cell collection.Posted onMay 7, 2021 1:48 pm

How can ww assess the immune system at diagnosis?Posted onMay 7, 2021 1:48 pm

What is/are the mechanism of resistance to daratumumab ? Is it about loss of CD38?Posted onMay 7, 2021 1:23 pm

Couldn't you discuss how long we have to trat CMM? Till progression?Posted onMay 7, 2021 1:08 pm

Dr Stewart- Yuo say that you stop maint treatment after 2 MRD negative, with thinking about resisance. This rull is not exist for you in RELAPSE MM? Lets Say after 4 years of DRd.... second line (MRD pos or neg)Posted onMay 7, 2021 12:51 pm

Do you cut double-drugged maintenane in high risk or double hit MM? Turn to one drug or or no drug? (Anil Ozturkmen, Turkey)Posted onMay 7, 2021 12:47 pm

Despite all of these fancy risk studies, we are still giving the same treatment to all patients? Is this just about conservatism? Or we are not ready yet?Posted onMay 7, 2021 12:43 pm

To Keith Stewart: Based on your remarks to avoid resistance have you stopped giving maintenance ? Meral Beksac TurkeyPosted onMay 7, 2021 12:41 pm

Any role for circulating tumor cells in defining disease risk?Posted onMay 7, 2021 12:40 pm

Should all patients with t(11,14) receive venetoclax based combinations?Posted onMay 7, 2021 12:38 pm

t(14;16) is good or poor or intermediate risk factor in 2021?Posted onMay 7, 2021 12:35 pm

What is the incidence of del17p in advanced disease?Posted onMay 7, 2021 12:34 pm

Hello, do mutations can dissapear ? We know clones can elvove, and MM becoming more HR, do you have case in the contrary ? Posted onMay 7, 2021 12:32 pm

Is there a correlation between myeloma treatment toxicity profiles and cytogenetic state of patientPosted onMay 7, 2021 12:32 pm

We give so much importance to ccf in evaluating 17p. Is this important in every situation? For example if a patient has a %20 plasma cells in bone marrow with %70 ccf and another patient has %70 plasma cells in bone marrow with %30 ccf. Or a patient whose plasme cells is %90 in bone marrow but ccf is %15 has only len maintenance but another patient has %15 plasma cells in bone marrow with % 90 ccf has VRd maintenance? Which is more important, ccf or risky cell proportion in whole bone marrow plasma cells? (Anil Ozturkmen, Turkey)Posted onMay 7, 2021 12:32 pm

Can normal myeloma develop into high risk and if so under what conditions?Posted onMay 7, 2021 12:30 pm

Is there a strong biological rationale behind dual PI and IMiD-based post-transplant maintenance in high-risk patients?Posted onMay 7, 2021 12:29 pm

Where do we stand with NGS and myeloma?Posted onMay 7, 2021 12:27 pm

Given the beautiful presentations, can we afford in this 3rd decade of the 21st century not having some form of NGS technology in our clinical practice of myeloma.Posted onMay 7, 2021 12:27 pm

Is the % of cells bearing del17p still a matter of importance?Posted onMay 7, 2021 12:26 pm

What is the minimal cytogenetics work up to perform?Posted onMay 7, 2021 12:24 pm

If a patient is resistant to a given triplet or quadruplet combination, is there a method to decipher whether the patient is resistant to all the drugs or only one rot would?Posted onMay 7, 2021 12:21 pm

What is the biological rationale for the usual recommendation to use proteasome inhibitors in high risk cytogenetics disease?Posted onMay 7, 2021 11:54 am

PATIENTS WHO PRESENT WITH RENAL FAILURE CAN BE CONSIDERED HIGH RISK DISEASE? Posted onMay 7, 2021 11:54 am

PATIENTS WHO PRESENT WITH RENAL FAILURE CAN BE CONSIDERED HIGH RISK DISEASE? Posted onMay 7, 2021 11:54 am

Is t(4,!4) a truly high risk myeloma?Posted onMay 7, 2021 11:52 am

Zvika Zilberman, Israel: what data do we know about combinations of affected chromosomes, one is high risk (e.g. t(14;16), t(4;14)), and another chromosome (e.g. 1q21) with regards to OS, CAR-T effectiveness, BMT Tandem effectiveness, etc.Posted onMay 7, 2021 11:51 am

Why do you n ot measure Thymidine kinase for proliferative activity? HJ Kolb Germany Posted onMay 7, 2021 11:50 am

Posted onMay 7, 2021 11:48 am

Posted onMay 7, 2021 11:44 am

is there any relation with genetic alterations and clinical presentation Marcos Hernandez VenezuelaPosted onMay 7, 2021 11:44 am

Posted onMay 7, 2021 11:43 am

Posted onMay 7, 2021 11:43 am

Posted onMay 7, 2021 11:43 am

session1+++++++++++++++++++++++++++++++++++++++++++++++++ Posted onMay 7, 2021 11:31 am

Posted onMay 7, 2021 11:15 am

role of allogeneic transplantation for myeloma? In our experience these are the only 20 year DF survivors! HJ Kolb GermanyPosted onMay 7, 2021 11:15 am

role of allogeneic transplantation in multiple myeloma? So far these are the only DFS for > 20 years!Posted onMay 7, 2021 11:14 am

Posted onMay 7, 2021 11:04 am

Posted onMay 7, 2021 11:04 am

Thank you for a lovely sympoPosted onMay 7, 2021 11:04 am

This is an amazing overview of the BCMA arena. Congratulations dr Gay and Dr TrudelPosted onMay 7, 2021 10:59 am

In my clinical practice I see that I can give Belamaf every 3-4 months (d/t corneal toxicity) and the response is reserve. Does the 3 weeks period per cycle is the best?Posted onMay 7, 2021 10:58 am

Posted onMay 7, 2021 10:55 am

Does Belantamab and anti-BCMA BITEs cause same severe hypogammaPosted onMay 7, 2021 10:55 am

Any thoughts on combining belantamab and alkylation going agents?Posted onMay 7, 2021 10:55 am

When I enter a young patient to a DREAM-X clinical trail- whould you esitate because he may not be a good candidate to CART later ?Posted onMay 7, 2021 10:53 am

When I enter a young patient to a DREAM-X clinical trail- whould you esitate because he may not be a good candidate to CART later ?Posted onMay 7, 2021 10:53 am

Posted onMay 7, 2021 10:52 am

ADCs do not need CD3 cells. The other options need some T cells… could this be a criteria for choosing the sequence?Posted onMay 7, 2021 10:49 am

What are there preventative measures of combination strategies induced toxicityPosted onMay 7, 2021 10:47 am

What is the biological rationale to combine belantamab and selinexor?Posted onMay 7, 2021 10:32 am

May I include Dr. Suzanne Trudel to my earlier inquiry please? (Kamuyu)Posted onMay 7, 2021 10:30 am

Is the loss of BCMA can be observed after ADCs?Posted onMay 7, 2021 10:26 am

How frequently we should send the patient to see the Ophtalmologist?Posted onMay 7, 2021 10:18 am

How one can sequence the different products targeting BCMA?Posted onMay 7, 2021 10:08 am

Are there any preventive measures one can apply to decrease the incidence of eye toxicity of belantamab?Posted onMay 7, 2021 10:07 am

During trial studies of those drugs did you factor in pharmacogenetics (as in their responses in different races) please? (To Dr. Francesca Gay). Regards- Kamuyu Mwai (Dr.) Integrated Sciences Research Scientist from KenyaPosted onMay 7, 2021 10:06 am

Posted onMay 7, 2021 9:30 am

*******************Posted onMay 7, 2021 8:55 am

Posted onMay 6, 2021 4:52 pm

Posted onMay 6, 2021 2:22 pm

Posted onMay 6, 2021 2:21 pm

Posted onMay 6, 2021 2:18 pm

Thank you for nice presentation Posted onMay 6, 2021 1:06 pm

b,cPosted onMay 6, 2021 1:01 pm

Posted onMay 6, 2021 12:50 pm

Role of stem cell therapy in treatment. Dr zahid from Islamabad Posted onMay 6, 2021 11:56 am

Posted onMay 6, 2021 11:34 am

Posted onMay 6, 2021 11:18 am

How to manage the Bortezomib induced Peripheral Neuropathy (Grade 4) in a Patient with R/R Plasma cell myeloma?Posted onMay 6, 2021 11:16 am

****** Springer ********Posted onMay 6, 2021 10:35 am

TestPosted onMay 5, 2021 8:51 pm